News and Announcements
Walker Capital completed $500,000 of Capital Raising and complete first phase of their investment platform
- Published December 18, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- 2018 has been a successful year for Walker Captial firstly completing $500,000 of their Capital Raising.
- Walker Capital has developed a free Net Return Investment Calculator
- The company have completed the first phase of their Investment Platform.
2018 has been a successful year for Walker Captial as they completed successfully completed $500,000 of their Capital Raising.
This has allowed us the company to complete the 1st phase of their Investment platform with full digital onboarding and KYC of Clients.
The foundations for the companies Marketing are in place and they look forward to solid growth in the new year.
Round 2 of the capital raise was a huge success and achieved $250,000.
The funds raised in Round 2 were used for marketing and the development of Walker Capital’s investment platform integration with their broker/counterparties.
Walker Capital will be expanding their Managed Investments to include securities.
The company has now commenced Round 3 of the capital raise.
Walker Capital has developed a free Net Return Investment Calculator which allows clients ad companies to simulate their investment in Walker Capital’s products based on real trading data.
The calculator can simulate clients investment in Walker Capital’s products based on real trading data over a selected investment period.
About Walker Capital
Walker Capital is to raise up to $900,000 for 20% in equity. The capital will be used to fund the expansion of the Company as it increases its marketing campaign aimed at expanding its client base and developing an investment platform for its clients.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
